Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Boosted by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 66.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,973 shares of the life sciences company's stock after acquiring an additional 4,797 shares during the quarter. B. Riley Wealth Advisors Inc.'s holdings in Illumina were worth $1,582,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $34,000. TD Private Client Wealth LLC lifted its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV lifted its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter worth $61,000. Finally, Private Trust Co. NA grew its stake in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after purchasing an additional 212 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.9 %

Shares of Illumina stock traded down $1.28 during trading hours on Tuesday, hitting $143.12. 1,771,055 shares of the company's stock traded hands, compared to its average volume of 2,008,106. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The company has a market cap of $22.70 billion, a PE ratio of -14.50 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a 50 day simple moving average of $144.35 and a 200-day simple moving average of $128.93.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the company posted $0.33 EPS. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research analyst reports. TD Cowen boosted their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. HSBC raised Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Argus upgraded Illumina from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research report on Wednesday, August 28th. UBS Group raised their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, Citigroup lowered shares of Illumina from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Illumina has a consensus rating of "Moderate Buy" and a consensus price target of $165.95.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.